针对费城阳性急性淋巴细胞白血病的迷你低密度脂蛋白血症、blinatumomab和泊纳替尼2期试验。

IF 10.1 1区医学 Q1 HEMATOLOGY

American Journal of Hematology Pub Date : 2024-08-28 DOI:10.1002/ajh.27463

Wei-Ying Jen, Elias Jabbour, Nicholas J Short, Ghayas C Issa, Fadi G Haddad, Nitin Jain, Naveen Pemmaraju, Naval G Daver, Lucia Masarova, Gautam Borthakur, Kelly Chien, Rebecca Garris, Hagop M Kantarjian

{"title":"针对费城阳性急性淋巴细胞白血病的迷你低密度脂蛋白血症、blinatumomab和泊纳替尼2期试验。","authors":"Wei-Ying Jen, Elias Jabbour, Nicholas J Short, Ghayas C Issa, Fadi G Haddad, Nitin Jain, Naveen Pemmaraju, Naval G Daver, Lucia Masarova, Gautam Borthakur, Kelly Chien, Rebecca Garris, Hagop M Kantarjian","doi":"10.1002/ajh.27463","DOIUrl":null,"url":null,"abstract":"Twenty adults with newly diagnosed (ND) or relapsed/refractory (RR) Ph-positive acute lymphoblastic leukemia (ALL), or chronic myeloid leukemia in lymphoid blast phase (CML-LBP), were treated with mini-hyperCVD, ponatinib, and blinatumomab. Complete molecular response was achieved in 78% of ND patients, while CR/CRi was achieved in 100% of RR and CML-LBP. The 3-year overall survival rate was 76% (95% CI, 47%-90%).","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.\",\"authors\":\"Wei-Ying Jen, Elias Jabbour, Nicholas J Short, Ghayas C Issa, Fadi G Haddad, Nitin Jain, Naveen Pemmaraju, Naval G Daver, Lucia Masarova, Gautam Borthakur, Kelly Chien, Rebecca Garris, Hagop M Kantarjian\",\"doi\":\"10.1002/ajh.27463\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Twenty adults with newly diagnosed (ND) or relapsed/refractory (RR) Ph-positive acute lymphoblastic leukemia (ALL), or chronic myeloid leukemia in lymphoid blast phase (CML-LBP), were treated with mini-hyperCVD, ponatinib, and blinatumomab. Complete molecular response was achieved in 78% of ND patients, while CR/CRi was achieved in 100% of RR and CML-LBP. The 3-year overall survival rate was 76% (95% CI, 47%-90%).\",\"PeriodicalId\":7724,\"journal\":{\"name\":\"American Journal of Hematology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":10.1000,\"publicationDate\":\"2024-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ajh.27463\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ajh.27463","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

20名新诊断（ND）或复发/难治（RR）Ph阳性急性淋巴细胞白血病（ALL）或淋巴细胞增生期慢性髓性白血病（CML-LBP）成人患者接受了迷你超白血病、泊纳替尼和blinatumomab治疗。78%的ND患者获得了完全分子反应，而100%的RR和CML-LBP患者获得了CR/CRi。3年总生存率为76%（95% CI，47%-90%）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.

Twenty adults with newly diagnosed (ND) or relapsed/refractory (RR) Ph-positive acute lymphoblastic leukemia (ALL), or chronic myeloid leukemia in lymphoid blast phase (CML-LBP), were treated with mini-hyperCVD, ponatinib, and blinatumomab. Complete molecular response was achieved in 78% of ND patients, while CR/CRi was achieved in 100% of RR and CML-LBP. The 3-year overall survival rate was 76% (95% CI, 47%-90%).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Hematology 医学-血液学

CiteScore

15.70

自引率

3.90%

发文量

363

审稿时长

3-6 weeks

期刊介绍： The American Journal of Hematology offers extensive coverage of experimental and clinical aspects of blood diseases in humans and animal models. The journal publishes original contributions in both non-malignant and malignant hematological diseases, encompassing clinical and basic studies in areas such as hemostasis, thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports highlighting innovative therapeutic approaches for the diagnosis and treatment of hematological diseases are actively encouraged.The American Journal of Hematology features regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, as well as letters and correspondence.